2026 World Down Syndrome Day
Together Against Loneliness

"Together Against Loneliness" not only calls for social inclusion but also emphasizes addressing the core health issues that lead to social isolation in patients through scientific research. Individuals with Down syndrome (DS) often face health challenges such as cognitive impairments, immune dysregulation, and heart defects, which limit their social participation. In-depth research into the mechanisms of targets like DYRK1A, APP, and IL-6, along with the development of intervention strategies to improve cognitive function and regulate immune balance, forms the scientific foundation for helping patients better integrate into society. The research reagents provided by CUSABIO are precisely aimed at supporting such translational research.

We select and classify targets based on the following principles:

• High-Frequency Literature: Selected from high-impact papers in recent DS research (e. g., Science, Nature, Science Translational Medicine)
• Pathological Correlation: Closely linked to the core phenotypes of DS (neurodevelopmental disorders, immune dysregulation, cardiac abnormalities)
• Mechanism Depth: Special focus on key genes of chromosome 21 (DYRK1A, RCAN1, APP) and their downstream signaling networks
• Drug Prospects: Inclusion of targets with therapeutic potential (such as pathways related to DYRK1A inhibitors)

Five major categories cover the research panorama from basic pathogenic mechanisms to multi-system complications.

Based on your research interests, you may refer to the following suggestions:

• Neurocognitive/Alzheimer's Disease Risk: Prioritize APP, APOE, Tau, BDNF, AKT1
• Immune Dysregulation/Autoimmunity: Focus on IL-6, TNF-α, CD4, STAT3, CRP
• Cardiac Development/Complications: Recommended ACE2, NFATc, DYRK1A, EGFR
• Drug target screening: Prioritize DYRK1A and its downstream signaling network targets.
• Oxidative Stress/Metabolism: SOD1, INS, TOM70 can be studied.

Yes! We offer the following customization services:

• Target Customization: For DS-related targets not listed in the table (e. g., antibodies for specific phosphorylation sites).
• Sample Testing: Utilizing ELISA kits for large-scale sample screening services
• Species Expansion: Existing products primarily cover humans, mice, and rats, with customization available for other species.
• Custom Labeling: Antibodies can be customized with various labels (FITC, HRP, Biotin, etc.).

Welcome Contact us for immediate consultation

All products displayed on the page are research reagents, intended for laboratory research use only (RUO) and are not suitable for clinical diagnosis or treatment. Our quality control system ensures the stability and reproducibility of the products in research applications.

Current trends in DS research include the following:

• From Gene Dosage to Pathway Regulation: Focusing on the Signaling Networks of Key Kinases such as DYRK1A
• From Single Target to Multi-System Intervention: Exploring the Cross-Regulation of Immune-Neuro-Metabolism
• From Basic Mechanisms to Translational Research: Small Molecule Drugs Such as DYRK1A Inhibitors Enter Preclinical Validation

CUSABIO will continue to track cutting-edge advancements, prioritizing the development of research reagents for hot targets (such as DYRK1A, NFATc, TOM70), providing high-quality tool support for DS researchers.